Skip to main content
Deciphera
  • Our Company
    • Who We Are
    • Leadership
  • Focus Areas
    • Overview
    • Oncology
    • Neurology
    • Immunology
  • Pipeline
    • Ongoing Clinical Trials
    • Presentations & Publications
  • Patients & Care Partners
    • Expanded Access
  • Healthcare Professionals (Coming soon!)
  • Our Medicines
  • Join Us
    • Our Culture
    • Open Positions
  • News

07/19/2024

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Read More

07/19/2024

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Read More

© 2026 Deciphera. All Rights Reserved.

  • Privacy Policy
  • Contact Us
  • Terms of Use
linkedin twitter
Back to top